

FIGURE 1

		IV+ORAL TREATMENT:												ORAL TREATMENT:								FOLLOW UP:								
WEEK:	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	124	28	32	36	40				
ORAL TREATMENT	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x									
	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2									
PHYSICIAN VISIT	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x		
SMA (6)	x																					x	x	x	x	x	x	x		
CBC	x																					x	x	x	x	x	x	x		
HCV-PCR RNA QUANTITATIVE	x																					x	x	x	x	x	x	x		
ANTI HCV	x																													
ANTI HCV CONFIRMATION	x																													
HCV-PCR GENOTYPE	x																													
CRYOGLOBULINS	x																													
LIVER BIOPSY	x																													
ABDOMINAL US	x																													
PT, PTT	x																					x	x	x	x	x	x	x	x	
AFP	x																													
NH3	x																													
ESR	x																													
ANF	x																													
C3	x																													
ANTI MITOCHONDRIA	x																													
ANTI SMOOTH MUSCLE	x																													
ANTI PARIELTAL CELL	x																													
IEP	x																													
HIV	x																													
HBSAG	x																													
ANTI HBC	x																													
ANTI HAV	x																													
ANTI CMV	x																													
ANTI EBV	x																													

BEST AVAILABLE COPY

FIGURE 2

SCORING & GRADING SYSTEMS

Table 1. HAI for numerical scoring of liver biopsy specimens

I. Periportal +/- Bridging Necrosis	Score	II. Intralobular Degeneration* and Focal Necrosis	Score	III. Portal Inflammation	Score	IV. Fibrosis	Score
A. None	0	A. None	0	A. No portal inflammation	0	A. No fibrosis	0
B. Mild piecemeal necrosis	1	B. Mild (acidophilic bodies, ballooning degeneration and/or scattered foci of hepatocellular necrosis in <1/3 of lobules or nodules)	1	B. Mild (sprinkling of inflammatory cells in <1/3 of portal tracts)	1	B. Fibrous portal expansion	1
C. Moderate piecemeal necrosis (involves less than 50% of the circumference of most portal tracts)	3	C. Moderate (involvement of 1/3-2/3 of lobules or nodules)	3	C. Moderate (increased inflammatory cells in 1/3- 2/3 of portal tracts)	3	C. Bridging fibrosis (portal-portal or portal- central linkage)	3
D. Marked piecemeal necrosis (involves more than 50% of the circumference of most portal tracts)	4	D. Marked (involvement of >2/3 of lobules or nodules)	4	D. Marked (dense packing of inflammatory cells in >2/3 of portal tracts)	4	D. Cirrhosis†	4
E. Moderate piecemeal necrosis <i>plus</i> bridging necrosis‡	5						
F. Marked piecemeal necrosis <i>plus</i> bridging necrosis‡	6						
G. Multilobular necrosis§	10						

NOTE. HAI score is the combined scores for necrosis, inflammation, and fibrosis.

*Degeneration—acidophil bodies, ballooning; focal necrosis—scattered foci of hepatocellular necrosis.


†Loss of normal hepatic lobular architecture with fibrous septae separating and surrounding nodules.

‡Bridging is defined as ≥2 bridges in the liver biopsy specimen; no distinction is made between portal-portal and portal-central linkage.

§Two or more contiguous lobules with pantlobular necrosis.


Modified and reprinted with permission.¹

FIGURE 3




BEST AVAILABLE COPY

FIGURE 4




BEST AVAILABLE COPY

FIGURE 5


BEST AVAILABLE COPY

FIGURE 6




BEST AVAILABLE COPY

FIGURE 7



BEST AVAILABLE COPY

FIGURE 8



BEST AVAILABLE COPY